Disease relevance of Cystadenocarcinoma, Mucinous

• A 36-yr-old woman with metastatic mucinous cystadenocarcinoma of the pancreas underwent neurolytic celiac plexus block with 100% ethanol and 0.5% bupivacaine for intractable back pain [1].
• Gonadotropin-releasing hormone messenger ribonucleic acid was detected in two of two mucinous cystadenocarcinoma specimens, one of one serous cystadenocarcinoma, and SK-OV3 cells but not in the dysgerminoma, mucinous cystadenoma, and normal ovary and placenta [2].
• GM-CSF also enhanced the colony formation by cells obtained from fresh ascites of a patient with ovarian mucinous cystadenocarcinoma and a patient with serous papillary ovarian carcinoma [3].
• Pancreatic beta cells in normal islets from adenocarcinoma and mucinous cystadenocarcinoma patients also expressed NGF [4].
• Successful pregnancy in a patient with pseudomyxoma peritonei arising from ovarian mucinous cystadenocarcinoma treated with cisplatin [5].

High impact information on Cystadenocarcinoma, Mucinous

• In mucinous cystadenocarcinoma, galactosylceramide is found in the relatively high concentration and is also composed of N-cerebronoyl phytosphingosine [6].
• Cyst fluids from mucinous cystadenocarcinoma of the ovary show significant concentrations of carcinoembryonic antigen (CEA) activity [7].
• Four unusual cases of primary mammary mucinous cystadenocarcinoma composed predominantly of tall columnar cells with abundant intracytoplasmic mucin are reported; they were multicystic and appeared virtually identical to mucinous cystadenocarcinomas of the ovary and pancreas [8].
• Hepatobiliary and pancreatic mucinous cystadenocarcinomas with mesenchymal stroma: analysis of estrogen receptors/progesterone receptors and expression of tumor-associated antigens [9].
• We used paraffin tissue immunohistochemical analysis with an appropriate panel of monoclonal antibodies to look for estrogen and progesterone receptors in two cases of hepatobiliary mucinous cystadenocarcinoma with mesenchymal stroma and one case of pancreatic mucinous cystadenocarcinoma [9].

Chemical compound and disease context of Cystadenocarcinoma, Mucinous

• In epithelial tumours, which constitute the majority of ovarian malignancies, mostly serous and mucinous cystadenocarcinomas, some tumour products have been described, which may have potential as a marker, for example, ovarian cancer associated antigens, some glycoprotein glycosyltransferases, and also carcinoplacental alkaline phosphatases (CPAP) [10].
• CONCLUSION: Paclitaxel and carboplatin may be effective in treating mucinous cystadenocarcinoma of the ovary [11].
• An ovarian mucinous cystadenocarcinoma which moderately accumulated Tc-99m MDP was imaged during a whole body bone scan [12].

Biological context of Cystadenocarcinoma, Mucinous

• In cystic tumors of the pancreas, p53 protein overexpression and DNA aneuploidy are rare events, restricted to malignant cases, mostly mucinous cystadenocarcinomas [13].
• Cytogenetic analysis was performed on tissue obtained from a patient undergoing repeat evacuation of mucin and mucin-producing implants in pseudomyxoma peritonei originating from an ovarian mucinous cystadenocarcinoma of low malignant potential [14].

Anatomical context of Cystadenocarcinoma, Mucinous

• Among them, a mucinous cystadenocarcinoma cell line also secreted tissue-type plasminogen activator, plasmin-like enzyme and trypsinogen [15].

Gene context of Cystadenocarcinoma, Mucinous

• EGF, cripto, and EGFR expression was significantly higher in mucinous cystadenocarcinomas than in mucinous cystadenomas or mucinous tumors of LMP [16].
• In mucinous cystadenocarcinomas, SP1, was present in 53.3% of cases, PP5 in 80.0%, PP10 in 20.0%, PP11 in 66.7% and PP12 in 46.7% [17].
• It is concluded that plasma CEA is of value in the management of patients with ovarian mucinous cystadenocarcinoma [18].
• A case of primary mucinous cystadenocarcinoma of the appendix with elevated serum carcinoembryonic antigen (CEA) [19].
• When the positive rate was compared according to histologic types, serous cystadenocarcinoma, mucinous cystadenocarcinoma, endometrioid adenocarcinoma and clear cell carcinoma showed the highest positive rates for CA125 (94.1%), CA19-9 (76.9%), CA125 (91.7%) and STN (75.0%), respectively [20].

Analytical, diagnostic and therapeutic context of Cystadenocarcinoma, Mucinous

• Complete response of a stage IV mucinous cystadenocarcinoma of the ovary to systemic chemotherapy employing paclitaxel and carboplatin [11].

References